File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II

TitleA randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2012
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2012 Annual Meeting of the American Society of Clinical Oncology® (ASCO 2012), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15_suppl., abstract no. 7519 How to Cite?
AbstractBACKGROUND: FASTACT, a randomized, phase 2 study in advanced NSCLC, found that intercalated erlotinib with 1st-line platinum-based chemotherapy (CT) significantly prolongs progression-free survival (PFS) (HR 0.47, p=0.0002) versus CT alone (Mok et al. JCO 2009). FASTACT-II is a confirmatory, randomized, phase 3, placebo-controlled, double-blind study in a large patient population METHODS: Patients with untreated stage IIIB/IV NSCLC and ECOG PS 0/1 were randomized (1:1) to receive up to 6 cycles of gemcitabine (1,250 mg/m2 on d1 and 8) plus platinum (carboplatin 5×AUC or cisplatin 75 mg/m2 on d1) q4w, with either intercalated erlotinib (150 mg/day on d15–28) or placebo. Non-...
DescriptionPoster Discussion Session: Lung Cancer - Non-small Cell Metastatic: abstract no. 7519 - http://meetinglibrary.asco.org/content/93895-114
Persistent Identifierhttp://hdl.handle.net/10722/194784
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorMok, Ten_US
dc.contributor.authorWu, YLen_US
dc.contributor.authorThongprasert, Sen_US
dc.contributor.authorYu, CJen_US
dc.contributor.authorZhang, Len_US
dc.contributor.authorLadrera, GEen_US
dc.contributor.authorSrimuninnimit, Ven_US
dc.contributor.authorSriuranpong, Ven_US
dc.contributor.authorSandoval-Tan, Jen_US
dc.contributor.authorZhu, Yen_US
dc.contributor.authorLiao, Men_US
dc.contributor.authorZhou, Cen_US
dc.contributor.authorPan, Hen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorChen, YMen_US
dc.contributor.authorSun, Yen_US
dc.contributor.authorMargono, Ben_US
dc.contributor.authorJin, Ken_US
dc.contributor.authorTruman, Men_US
dc.contributor.authorLee, JSen_US
dc.date.accessioned2014-02-17T02:09:50Z-
dc.date.available2014-02-17T02:09:50Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 Annual Meeting of the American Society of Clinical Oncology® (ASCO 2012), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15_suppl., abstract no. 7519en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/194784-
dc.descriptionPoster Discussion Session: Lung Cancer - Non-small Cell Metastatic: abstract no. 7519 - http://meetinglibrary.asco.org/content/93895-114-
dc.description.abstractBACKGROUND: FASTACT, a randomized, phase 2 study in advanced NSCLC, found that intercalated erlotinib with 1st-line platinum-based chemotherapy (CT) significantly prolongs progression-free survival (PFS) (HR 0.47, p=0.0002) versus CT alone (Mok et al. JCO 2009). FASTACT-II is a confirmatory, randomized, phase 3, placebo-controlled, double-blind study in a large patient population METHODS: Patients with untreated stage IIIB/IV NSCLC and ECOG PS 0/1 were randomized (1:1) to receive up to 6 cycles of gemcitabine (1,250 mg/m2 on d1 and 8) plus platinum (carboplatin 5×AUC or cisplatin 75 mg/m2 on d1) q4w, with either intercalated erlotinib (150 mg/day on d15–28) or placebo. Non-...en_US
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleA randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-IIen_US
dc.typeConference_Paperen_US
dc.identifier.emailLee, V: vhflee@hku.hken_US
dc.identifier.authorityLee, V=rp00264en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros227945en_US
dc.identifier.volume30en_US
dc.identifier.issue15_suppl.en_US
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats